Microcap Ledger Aclaris Therapeutics, Inc. $ACRS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Wayne, PA
- Fiscal year end
- December 31
- Shares outstanding
- 147,198,893 [10-Q 2026-08-06]
What the company doesAI summary of filing
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing product candidates, including bosakitug, ATI-052, and ATI-2138, for which it intends to identify and consummate partnerships with third-party companies for further development, regulatory approval, and commercialization. The company does not currently generate revenue from product sales and relies on third parties for clinical trial conduct, manufacturing, and distribution of its product candidates. The company's ability to earn revenue depends on successfully partnering with pharmaceutical or biotechnology companies, obtaining regulatory approvals, and achieving adequate reimbursement coverage from government and private payors. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $3.63M | −$41.33M | −$38.00M | $19.17M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $7.83M | −$64.92M | −$47.11M | $19.96M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $18.72M | −$132.06M | −$20.07M | $24.57M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$19.00M
- Cash runway Estimate
- ~3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 71,430,942 | [10-Q 2024-11-06] |
| 2025-01-31 | 107,918,821 | [10-K 2025-02-27] |
| 2025-04-30 | 108,281,239 | [10-Q 2025-05-08] |
| 2025-07-31 | 108,332,218 | [10-Q 2025-08-07] |
| 2025-10-31 | 108,345,239 | [10-Q 2025-11-06] |
| 2026-01-30 | 120,595,189 | [10-K 2026-02-26] |
| 2026-04-30 | 139,663,680 | [10-Q 2026-05-07] |
| 2026-07-31 | 147,198,893 | [10-Q 2026-08-06] |
- Shelf registration
- S-3ASR filed 2026-08-06 [S-3ASR 2026-08-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-01 | Kolbeck Roland Wilhelm | exercise | 36,375 | — | [4 2026-08-04] |
| 2026-08-01 | Kolbeck Roland Wilhelm | other | 12,385 | $5.20 | [4 2026-08-04] |
| 2026-06-05 | Mehra Anand | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-06-05 | Schiff Andrew N | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-06-05 | Humphries William D. | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-06-05 | Molineaux Christopher P. | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-06-05 | Milano Vincent | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-06-05 | Gowen Maxine | exercise | 11,580 | — | [4 2026-06-08] |
| 2026-05-01 | Hall Jesse Wayne | exercise | 36,375 | — | [4 2026-05-05] |
| 2026-05-01 | Hall Jesse Wayne | other | 9,330 | $4.41 | [4 2026-05-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-21 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Material agreement entered |
| 2026-08-06 | S-3ASR | Registration statement |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-04 | 8-K | Shareholder vote results |
| 2026-05-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-28 | 8-K | Regulation FD disclosure; Other events |
| 2026-04-27 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $ACRS
Email me when Aclaris Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.